INGN Quote, Financials, Valuation and Earnings

Alphatec Holdings has a net margin of -12.18% compared to Inogen's net margin of -30.68%. Inogen's return on equity of -19.02% beat Alphatec Holdings's return on equity of -691.37%.

Inogen has a consensus price target of $9.50, signalling upside risk potential of 49.61%. On the other hand Alphatec Holdings has an analysts' consensus of $18.21 which suggests that it could grow by 42.92%. Given that Inogen has higher upside potential than Alphatec Holdings, analysts believe Inogen is more attractive than Alphatec Holdings.

Inogen has a beta of 1.632, which suggesting that the stock is 63.248% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.249%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $80.1M, which are smaller than Alphatec Holdings quarterly revenues of $169.2M. Inogen's net income of -$9.8M is higher than Alphatec Holdings's net income of -$51.9M. Notably, Inogen's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.45x versus 2.86x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -12.18% compared to Inogen's net margin of -45.89%. Inogen's return on equity of -19.02% beat Masimo's return on equity of -39.91%.

Inogen has a consensus price target of $9.50, signalling upside risk potential of 49.61%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 18.55%. Given that Inogen has higher upside potential than Masimo, analysts believe Inogen is more attractive than Masimo.

Inogen has a beta of 1.632, which suggesting that the stock is 63.248% more volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $80.1M, which are smaller than Masimo quarterly revenues of $372M. Inogen's net income of -$9.8M is higher than Masimo's net income of -$170.7M. Notably, Inogen's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.45x versus 4.22x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Milestone Scientific has a net margin of -12.18% compared to Inogen's net margin of -58.13%. Inogen's return on equity of -19.02% beat Milestone Scientific's return on equity of -61.33%.

Inogen has a consensus price target of $9.50, signalling upside risk potential of 49.61%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 118.79%. Given that Milestone Scientific has higher upside potential than Inogen, analysts believe Milestone Scientific is more attractive than Inogen.

Inogen has a beta of 1.632, which suggesting that the stock is 63.248% more volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.585%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $80.1M, which are larger than Milestone Scientific quarterly revenues of $2.5M. Inogen's net income of -$9.8M is lower than Milestone Scientific's net income of -$1.5M. Notably, Inogen's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.45x versus 8.96x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -12.18% compared to Inogen's net margin of -2.16%. Inogen's return on equity of -19.02% beat Myomo's return on equity of -48.64%.

Inogen has a consensus price target of $9.50, signalling upside risk potential of 49.61%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 169.35%. Given that Myomo has higher upside potential than Inogen, analysts believe Myomo is more attractive than Inogen.

Inogen has a beta of 1.632, which suggesting that the stock is 63.248% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Inogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Inogen quarterly revenues are $80.1M, which are larger than Myomo quarterly revenues of $12.1M. Inogen's net income of -$9.8M is lower than Myomo's net income of -$260.1K. Notably, Inogen's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen is 0.45x versus 3.90x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.